Previous Article | Next Article 
Infection and Immunity, September 2001, p. 5423-5429, Vol. 69, No. 9
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.9.5423-5429.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Chlamydia pneumoniae Expresses Genes
Required for DNA Replication but Not Cytokinesis during Persistent
Infection of HEp-2 Cells
Gerald I.
Byrne,1,*
Scot P.
Ouellette,1
Zhao
Wang,2
J. P.
Rao,2
Lin
Lu,2
Wandy L.
Beatty,3 and
Alan P.
Hudson2
Department of Medical Microbiology and
Immunology, University of Wisconsin School of Medicine, Madison,
Wisconsin 537061; Department of
Immunology and Microbiology, Wayne State University School of
Medicine, Detroit, Michigan 482012; and
Department of Molecular Microbiology, Washington University
School of Medicine, St. Louis, Missouri 631103
Received 4 April 2001/Returned for modification 30 May
2001/Accepted 19 June 2001
 |
ABSTRACT |
Chlamydia pneumoniae causes community-acquired
pneumonia and is associated with several chronic diseases, including
asthma and atherosclerosis. The intracellular growth rate of C.
pneumoniae slows dramatically during chronic infection, and
such persistence leads to attenuated production of new elementary
bodies, appearance of morphologically aberrant reticulate bodies, and
altered expression of several chlamydial genes. We used an in vitro
system to further characterize persistent C. pneumoniae
infection, employing both ultrastructural and transcriptional activity
measurements. HEp-2 cells were infected with C.
pneumoniae (TW-183) at a multiplicity of infection of 3:1, and
at 2 h postinfection gamma interferon (IFN-
) was added to the
medium at 0.15 or 0.50 ng/ml. Treated and untreated cultures were
harvested at several times postinfection. RNA was isolated and reverse
transcribed, and reverse transcription (RT)-PCR analyses targeting
primary transcripts from chlamydial rRNA operons as well as
dnaA, polA, mutS,
minD, ftsK, and ftsW mRNA
were done. Some cultures were fixed and stained for electron microscopic analysis, and a real-time PCR assay was used to assess relative chlamydial chromosome accumulation under each culture condition. The latter assays showed that bacterial chromosome copies
accumulated severalfold during IFN-
treatment of infected HEp-2
cells, although less accumulation was observed in cells treated with
the higher dose. Electron microscopy demonstrated that high-dose
IFN-
treatment elicited aberrant forms of the bacterium. RT-PCR
showed that chlamydial primary rRNA transcripts were present in all
IFN-
-treated and untreated cell cultures, indicating bacterial
metabolic activity. Transcripts from dnaA, polA, mutS, and minD, all
of which encode products for bacterial chromosome replication and
partition, were expressed in IFN-
-treated and untreated cells. In
contrast, ftsK and ftsW, encoding
products for bacterial cell division, were expressed in untreated
cells, but expression was attenuated in cells treated with low-dose
IFN-
and absent in cells given the high dose of cytokine. Thus, the development of persistence included production of transcripts for DNA
replication-related, but not cell division-related, genes. These
results provide new insight regarding molecular activities that
accompany persistence of C. pneumoniae, as well as
suggesting requirements for reactivation from persistent to productive growth.
 |
INTRODUCTION |
Chlamydia
pneumoniae and Chlamydia trachomatis are intracellular
bacterial pathogens that function as etiologic agents of important
human diseases. The former, for example, causes community-acquired pneumonia and has recently been associated with various chronic diseases such as asthma and atherosclerosis (9, 16).
C. trachomatis remains a significant cause of infectious,
preventable blindness (trachoma) in the developing world
(26) and is a sexually transmitted pathogen known to cause
fertility deficits in women (26), as well as chronic
arthritis in both sexes (for a review, see reference 14).
Infections with each organism show high rates of recurrence (3,
8), but currently available information usually does not allow
unequivocal differentiation between recurrences due primarily to
reinfection and those resulting from chronic, persistent infection.
However, the large number of published case reports provide some
evidence that C. pneumoniae can cause chronic respiratory infections, and these often are refractory to antibiotic therapy (10). Moreover, the increasingly strong association of
C. pneumoniae with such chronic conditions as follicular
conjunctivitis (19), adult-onset asthma (9),
and atherosclerosis (16, 23) provides substantiation that
this organism indeed can persist for extended periods in its human host.
Persistence of C. pneumoniae has been documented in various
animal models of infection (18, 20), and studies using
several cell culture model systems indicate that activation of
chlamydial host cells by immune-regulated cytokines elicits a
persistent growth state in this organism (22). This state
is nonproductive, involving generation of enlarged, aberrantly shaped,
nondividing C. pneumoniae reticulate bodies (RB) that do not
mature into infectious elementary bodies (EB). The result of this type
of chlamydia-host cell interaction is chronic infection that can be
maintained in cell culture for extended periods (17).
Several in vitro models of C. trachomatis persistence have
been characterized (1). Interestingly, in one such model
system ultrastructural analysis suggested that organisms of this
species made persistent in culture by treatment with gamma interferon (IFN-
) continue to replicate and partition their genomes, even in
the absence of subsequent cell division (2). This provides at least a partial explanation for the lack of production of new infectious EB by persistent C. trachomatis; however, no
congruent information is available as yet for persistent C. pneumoniae. The present study was undertaken to investigate
similar aspects of the molecular genetic behavior of persistent
C. pneumoniae, using a well-described cell culture model system.
Data from the chlamydial genome sequence have identified orthologs for
dnaA, polA, and mutS, each of which
encodes a gene product required for DNA replication and repair
(4) in C. pneumoniae; a minD
ortholog has also been identified, the product of which is required for
chromosome segregation (24). Chlamydiae apparently do not
have an ftsZ gene (24) but do possess orthologs
for ftsK and ftsW, each of which encodes a
product required for cell division (5). In the work
described here, we provide information regarding differential
expression of these C. pneumoniae DNA replication- and
cytokinesis-related genes under conditions of both persistent and
productive growth. Our results indicate that mRNA from C. pneumoniae genes encoding products required for chromosome
replication, repair, and segregation are synthesized regardless of
whether the organism is in a persistent or a productive growth state. Organisms undergoing productive infection express cytokinesis-related transcripts as expected, whereas persistent organisms do not. These
observations provide new information concerning the basic biology of
chlamydial persistence and may be useful in the design of improved
treatment regimens for chronic chlamydial infections.
 |
MATERIALS AND METHODS |
Cell culture and growth of C. pneumoniae.
The
human bronchial epithelial cell line HEp-2 was used for growth and
propagation of C. pneumoniae. HEp-2 cells were grown in
Iscove's modified Dulbecco's medium (BioWhittaker, Walkersville, Md.)
supplemented with 10% heat-inactivated fetal bovine serum (HyClone,
Logan, Utah), 50 µg of vancomycin (Sigma, St. Louis, Mo.) per ml, and
10 µg of gentamicin (Life Technologies, Gaithersburg, Md.) per ml.
Cells were routinely maintained at 35°C in 7%
CO2 in a water-jacketed CO2
incubator and passaged two or three times per week in
162-cm2 cell culture flasks (Corning Costar,
Cambridge, Mass.). C. pneumoniae TW-183 was purchased from
the American Type Culture Collection (Rockville, Md.) and propagated
for 3 days in HEp-2 cells treated with 2 µg of cycloheximide (Sigma)
per ml. Chlamydiae were collected from infected-cell sonicates by
differential centrifugation, partially purified by centrifugation
through a 30% Renografin (Bracco Diagnostics, Princeton, N.J.)
cushion, and resuspended in sucrose-phosphate buffer (SPB; 0.22 M
sucrose, 0.2 M NaH2PO4, 0.2 M Na2HPO4, 5 mM glutamic
acid [pH 7.4]), as described previously (15). Stock titers were determined, and stocks were stored at
80°C as described previously (15).
Infection and preparation of cells for nucleic acid
analyses.
HEp-2 cells were trypsinized from
162-cm2 flasks, plated onto six-well cell culture
plates (Corning Costar) at a density of 1.5 × 106 per well, and incubated overnight at 35°C
in 7% CO2. The next day, cells were infected at
a multiplicity of infection of 3 in 2 ml of SPB and centrifuged at
400 × g for 1 h at 30°C. Infected cells were
incubated at 35°C for 30 min with rocking. The inocula were then
aspirated, and fresh medium was added with or without specified amounts
(0.15 or 0.50 ng/ml) of human recombinant IFN-
(rIFN-
; Genzyme,
Cambridge, Mass.). Extra plates were infected and treated to monitor
the infection and condition of the host cells. These plates were fixed
in absolute methanol, stained with Giemsa, and observed microscopically
at each harvest time point. Cells were collected and processed for
nucleic acid analysis every 12 h postinfection for the duration of
the 96-h experiment. Uninfected control samples were processed at
48 h postinfection. For some control experiments, infected HEp-2
cell cultures were grown in the presence or absence of 2 pg of
cycloheximide per ml and harvested at specified times for analyses.
Cells from all cultures were collected and centrifuged, and pellets
were flash frozen at
80°C. Cells from three plates were pooled (18 wells) for each sample at each harvest time to ensure adequate
chlamydial DNA and RNA for analysis.
Ultrastructural analysis.
Monolayers of uninfected HEp-2
cells or cells infected for 48 h with C. pneumoniae and
treated with rIFN-
or left untreated were washed with
phosphate-buffered saline (PBS), and cells were gently removed from
culture dishes with a cell scraper. The cells were then collected by
centrifugation and fixed in 2% glutaraldehyde (electron microscopy
[EM] grade; Sigma) in PBS (pH 7.4) for 2 h at 4°C. Following
three washes in PBS, samples were fixed for 1 h at room
temperature in 1% osmium tetroxide in PBS. The samples were then
dehydrated in a graded series of ethanol and embedded in Spurr's
resin (Electron Microscopy Sciences, Ft. Washington, Pa.).
Sections of 70 to 80 nm were cut, stained with lead citrate and uranyl
acetate, and viewed on a Zeiss transmission electron microscope.
Infectivity assays.
Monolayers of HEp-2 cells were infected
with C. pneumoniae at a multiplicity of infection of 1 and
subsequently treated with rIFN-
at various doses 2 h
postinfection or left untreated. To mimic a typical growth curve, cell
sonicates were collected at 72 h and resuspended in SPB.
Chlamydial titers from each sample were determined as described for
infectivity (15).
Nucleic acid preparation.
Total nucleic acids were prepared
from snap-frozen pellets of infected and uninfected HEp-2 cells via
homogenization in 65°C buffered phenol and extensive extraction in
phenol-chloroform (24:1), as described elsewhere (6). DNA
was prepared for quantitative PCR analysis by treatment of total
nucleic acid preparations with RNase A plus RNase T1 (Life
Technologies). RNA was isolated from the preparations for reverse
transcription (RT)-PCR analysis by treatment with RNase-free DNase 1 (RQ1; Promega Biotech, Madison, Wis.). Each DNA and RNA preparation was
extensively extracted with phenol-chloroform and collected as an
ethanol precipitate (11). RNA preparations were
confirmed to be DNA free by PCR targeting the host
-actin gene in
the absence of RT. The integrity of RNA preparations was assessed by
visual analysis of ethidium bromide-stained formaldehyde-agarose
electrophoresis gels and by RT-PCR targeting of the host actin gene
(6, 11).
Real-time PCR analyses.
To assess the accumulation of
C. pneumoniae chromosome over time postinfection in host
cells treated with cycloheximide or rIFN-
or left untreated, we
adapted a highly quantitative real-time PCR assay system described and
tested by others (21). Briefly, the chlamydia-directed
primers target the two copies of the 16S rRNA gene on the bacterial
chromosome, while assay input is normalized simultaneously to host 18S
rRNA gene sequences. The C. pneumoniae-directed primers for
the assay were designed using software supplied for this purpose by PE
Biosystems (Foster City, Calif.); these primers were
5'-GTTGTTATTTAGTGGCGGAA-3' and
5'-CCCACCAACAAGCTGATA-3'. Extensive control studies
confirmed that only a single amplification product is generated by this
primer system and that the product is the appropriate segment of the
C. pneumoniae 16S rRNA coding sequence. The human
18S-directed primer system used for normalization was purchased from PE
Biosystems and was designed for this use. All assays were done several
times, each in triplicate, using a PE Biosystems model 7700 sequence
detector with the SYBR green method (12). Data from
real-time PCR assays were calculated using sequence detection software,
version 1.7, from PE Biosystems.
RT-PCR analyses.
RT was done as previously described
(6) with 5 µg of total RNA from each preparation, random
hexamers as primers, and murine leukemia virus reverse transcriptase
(Life Technologies). cDNA from each reaction was treated with RNase A,
RNase T1, and RNase H, extracted several times with phenol-chloroform
(24:1), and then collected as an ethanol precipitation (6,
11). The genes targeted in RT-PCR are given in Table
1, along with the primer sequences
employed for amplification. Primer sequences were designed using the
GeneRunner system (Hastings Software, Hastings, N.Y.) based on
published sequence information (http://stdgen.lanl.gov). Each primer
set was tested to confirm that chlamydial but not host cell sequences
were amplified; control experiments established that all assay systems
had approximately equivalent sensitivities and were able to identify
transcripts from 10 to 30 bacterial cells. Amplification conditions for
the first round of nested reactions were 4 min at 95°C, 35 cycles of
40 s at 95°C, 40 s at the annealing temperature, and
40 s at 72°C, and 10 min at 72°C. Annealing temperatures
varied somewhat among the several primer sets. The second nested
amplification round was done using similar cycling parameters and 10%
of the first-round reaction mixture. The positive control for
chlamydial transcriptional activity was demonstration of primary
transcripts from the bacterial rRNA operons, as previously described
(7). Amplifications were done using Ampli-Taq
DNA polymerase (Perkin Elmer) in a thermocycler (model PTC-100; MJ
Research, Watertown, Mass.). Products were visualized by ethidium
bromide staining of standard agarose electrophoretic gels
(11). Representative RT-PCR products were hybridized with internal chlamydial DNA probes to verify their authenticity.
Statistics.
Each real-time PCR assay was performed twice on
each of three separate cell preparations, and each tube in each assay
was run in triplicate. Standard errors were calculated for the results shown in Fig. 1 and 6 using Excel (Microsoft Corp., Seattle, Wash.).
 |
RESULTS |
Accumulation of chlamydial DNA and expression of DNA replication-
and cytokinesis-related genes during infection of HEp-2 cells.
C. pneumoniae completes the standard developmental cycle
within HEp-2 cells. However, growth of the organism in infected cell cultures is usually done in the presence of cycloheximide to increase the yield of infectious EB. To provide controls for the relative amount
of chlamydial DNA produced under various treatment conditions, including treatment with rIFN-
(see below), a highly quantitative real-time PCR assay targeting the C. pneumoniae 16S rRNA
genes was used. The data shown in Fig. 1
indicate that when chlamydial DNA levels were compared as a function of
incubation time in untreated and cycloheximide-treated HEp-2 cells, a
time-dependent increase occurred, and as expected, greater amounts of
chlamydial chromosome accumulated in cycloheximide-treated than
untreated host cells. Part of this observed increase may
have been due to less host 18S rRNA in cycloheximide-treated samples,
but chlamydial growth does occur to a greater extent in host cells
treated with cycloheximide. We found that at 96 h postinfection,
the final time point examined in these experiments, the
cycloheximide-treated cultures had accumulated in excess of 3.5-fold
more chlamydial DNA than the untreated culture. In the treated
cultures, accumulation of bacterial chromosome over 96 h was at
the level of about 270-fold, indicating seven to eight cell divisions
undertaken by each RB within the inclusions. Several repeats of these
determinations yielded virtually identical results.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 1.
Results of quantitative real-time PCR assays to
determine the relative level of accumulation of C.
pneumoniae chromosomal DNA over time during infection of
untreated ( Cx) and cycloheximide-treated (+Cx) HEp-2 cells. Cells
were infected with C. pneumoniae TW-183 as described in
Materials and Methods, and cultures were harvested at the times
indicated. Total DNA was prepared, and a real-time PCR assay system was
employed to determine the relative level of chlamydia DNA at each time
point. Input into each quantitative assay was normalized to the host
18S rRNA genes, as described in Materials and Methods. Data are
triplicate means plus standard errors and are expressed as fold
increase in chlamydial DNA over time relative to the value obtained at
12 h postinfection.
|
|
As a control for transcript-related experiments given below, the time
course of expression was determined for a panel of C. pneumoniae genes whose products are involved in replication and partition of the bacterial chromosome, as well as the cell division process, in untreated and cycloheximide-treated HEp-2 cells. Figure 2 shows representative results from these
nonquantitative RT-PCR studies. In both treated and untreated infected
HEp-2 cells, primary transcripts from the rRNA operons were apparent at
12 h postinfection, as was mRNA from adt1, which
specifies an ATP-ADP exchange protein of the organism. Similarly,
dnaA, polA, and ftsK all were being expressed by 12 h after initiation of infection, the earliest time
assayed in both treated and untreated cells; expression of each of
these genes continued through 96 h postinfection. Similar results
were obtained for mutS, minD, and ftsW
(data not shown).

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 2.
Representative RT-PCR analyses targeting C.
pneumoniae genes whose products are required for chromosomal
DNA replication and cell division, as a function of time in infection
of untreated ( CX) or cycloheximide-treated (+CX) HEp-2 cells. Cells
were infected with chlamydiae and harvested at the indicated times, and
RNA was prepared from each harvested culture (see Material and
Methods). RT-PCR analyses were performed using primers given in Table
1. (A) Primary rDNA transcripts; (B) adt1 transcript;
(C) dnaA transcript; (D) polA transcript;
(E) ftsK transcript. Lanes: C+, positive PCR controls
for each primer set, using C. pneumoniae DNA as the
amplification template; C , negative RT-PCR controls using cDNA from
uninfected HEp-2 cells as the amplification template; RT , negative
control showing the results of PCR with each primer set in the absence
of RT of RNA preparations used; ACT, amplification product from an
RT-PCR assay targeting host -actin mRNA. Input into each assay was
normalized to the host -actin transcript. Sizes of the amplification
products: primary rRNA, 609 bp; adt1, 433 bp; host
actin, 550 bp; dnaA, 410 bp; polA, 405 bp; ftsK, 238 bp.
|
|
Effects of IFN-
on C. pneumoniae development and
ultrastructure in IFN-
-treated HEp-2 cells.
Treatment of HEp-2
cells with rIFN-
2 h after infection with C. pneumoniae caused a dose-dependent inhibition of infectivity recovery (Fig. 3). Transmission EM of
infected HEp-2 cells demonstrated classic EB and RB developmental forms
48 h postinfection (data not shown). When cells were treated with
subinhibitory doses of rIFN-
, normal-appearing inclusions also were
observed after 48 h of growth (Fig.
4A). In contrast, infected HEp-2 cells
treated with 0.5 ng of rIFN-
per ml for 48 h demonstrated
essentially universal development of enlarged persistent forms, as
judged from EM (Fig. 4B). This form of the organism is indicative of noninfectious, poorly dividing, greatly enlarged, and aberrantly shaped
RB and is known to be a result of IFN-
-mediated induction of the
tryptophan-decyclizing enzyme indoleamine-2,3-dioxygenase, which limits
availability of the required amino acid tryptophan (1).
The presence of these aberrant forms was used as a basis for comparison
of selected transcriptional activities with organisms progressing
through a productive infection in HEp-2 cells.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of IFN- on C. pneumoniae growth
in HEp-2 cells. Cells were treated with the indicated amounts of
IFN- 2 h postinfection and assayed for infectivity after 3 days
of incubation. Results are means for individual samples from each
treatment group as a function of the averaged untreated control. All
samples were assayed in triplicate, and standard deviations are shown.
Samples from cells exposed to 0.15 and 0.5 ng of IFN- per ml were
used for ultrastructural analyses.
|
|

View larger version (108K):
[in this window]
[in a new window]
|
FIG. 4.
Ultrastructural analysis by transmission EM of HEp-2
cells persistently infected for 48 h with C.
pneumoniae. (A) Treatment with low levels of IFN- (0.15 ng/ml) resulted in the development of typical inclusions containing EB
and RB. Normal RB are indicated by arrows. (B) Treatment with 0.50 ng
of IFN- per ml to induce persistence engenders development of
grossly enlarged RB (arrowheads). N, nucleus. Bar = 1 µm.
|
|
Viability of C. pneumoniae in untreated and
rIFN-
-treated HEp-2 cell cultures.
To determine if the
morphologically aberrant chlamydiae observed in EM studies exhibit
metabolic activity, infected HEp-2 cells treated for 48 h with
0.15 or 0.5 ng of rIFN-
per ml were assessed for the presence of
primary transcripts from the chlamydial rRNA operons. These transcripts
were detectable by RT-PCR by 12 h postinfection in
chlamydia-infected cells not treated with rIFN-
, and their
expression continued through 96 h (Fig. 2); similarly, the
chlamydial adt1 gene was expressed from 12 to 96 h
postinfection in untreated cells. Transcripts from these genes were not
detectable in chlamydial EB but were demonstrable in infected HEp-2
cells treated with either high- or low-dose rIFN-
(Fig.
5). These data support the contention
that while C. pneumoniae organisms grown in the presence of
rIFN-
assume an aberrant morphologic form, they do remain viable, as
judged by the presence of RNA species characteristic of metabolically
active bacteria.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 5.
Representative RT-PCR analyses targeting primary
transcripts from the C. pneumoniae rRNA operons (A) and
adt1 (B) in untreated infected HEp-2 cells and infected
HEp-2 cells treated with low or high doses of rIFN- . Cells were
infected with chlamydiae and harvested at 48 h posttreatment, and
RNA was prepared from each harvested culture (see Material and
Methods). RT-PCR analyses were performed using primers given in Table
1. Lanes: C+, positive PCR control for each primer set, using C.
pneumoniae DNA as the amplification template. C , negative
RT-PCR control using cDNA from uninfected HEp-2 cells as the
amplification template; RT , negative control showing the results of
PCR with each primer set in the absence of RT of RNA preparations used;
Act, amplification product from an RT-PCR assay targeting host
-actin mRNA; EB, amplification product from pure EB RNA. Sizes of
the amplification products are given in the legend to Fig. 1.
|
|
Chromosome replication in rIFN-
-treated C.
pneumoniae.
The control experiments described above
indicated that replication of the chlamydial chromosome was under way
by 24 h postinfection in both untreated and cycloheximide-treated
infected HEp-2 cells (Fig. 1). When the relative levels of C. pneumoniae DNA were compared in untreated cells and those treated
for 48 h with 0.15 or 0.5 ng of rIFN-
per ml, evidence for
bacterial chromosome replication in the IFN-
-treated samples was
observed (Fig. 6). Clearly, less bacterial DNA was produced in the cultures treated with 0.5 ng of
IFN-
per ml than in untreated cultures, but these data confirm the
contention that persistent C. pneumoniae are metabolically active and that aberrant chlamydial morphology and growth did not cause
complete inhibition of genome replication.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 6.
Results from quantitative real-time PCR assays to
determine the relative level of accumulation of C.
pneumoniae chromosomal DNA during infection of untreated
infected HEp-2 cells and infected HEp-2 cells treated with either 0.15 or 0.50 ng of rIFN- per ml. Cells were infected with C.
pneumoniae TW-183 as described in Materials and Methods. Both
treated and untreated cultures were grown without cycloheximide and
were harvested at 48 h postinfection or posttreatment. DNA was
prepared, and a real-time PCR assay system was used to determine the
relative level of Chlamydia DNA from each preparation.
Input into each assay was normalized to the host 18S rRNA genes, as
described in Materials and Methods. Data are triplicate mean values
relative to the mean value obtained for untreated cells at 12 h
postinfection (not shown). Standard errors are indicated.
|
|
Expression of chlamydial DNA replication- and cytokinesis-related
genes in untreated and rIFN-
-treated infected HEp-2 cells.
Control studies (Fig. 2) clearly indicated that the chlamydial
dnaA, polA, ftsK, and ftsW
genes are expressed as early as 12 h postinfection in HEp-2 cells,
regardless of whether the cells are treated with cycloheximide. To
determine whether these chlamydial DNA replication- and
cytokinesis-related genes are expressed during persistent growth
induced by cytokine treatment, we assessed the presence of mRNA
encoding them in RNA prepared from infected HEp-2 cells treated for
48 h with 0.15 or 0.50 ng of rIFN-
per ml. As indicated by
representative assays (Fig. 7),
chlamydial DNA replication- and partition-related genes were expressed
in rIFN-
-treated infected HEp-2 cultures regardless of the cytokine
concentration in the growth medium. However, amplification products of
the chlamydial ftsK and ftsW genes, whose
products are required for cell division, were attenuated in cultures
treated with 0.15 ng of rIFN-
per ml, and they were not found in RNA
or cDNA preparations from cells grown with the higher cytokine
concentration.

View larger version (80K):
[in this window]
[in a new window]
|
FIG. 7.
Representative RT-PCR analyses targeting transcripts
from C. pneumoniae DNA replication- and cell
division-related genes in untreated infected HEp-2 cells and infected
HEp-2 cells treated with low or high doses of rIFN- . Cells were
infected with chlamydiae and harvested at 48 h posttreatment, and
RNA was prepared from each harvested culture (see Material and
Methods). RT-PCR analyses were performed using primers given in Table
1. (A) primary rRNA transcripts; (B) dnaA; (C)
polA; (D) ftsK. Lanes: C+, positive PCR
control for each primer set, using C. pneumoniae DNA as
the amplification template; C , negative RT-PCR control, using cDNA
from uninfected HEp-2 cells as the amplification template; RT ,
negative control showing the results of PCR with each primer set in the
absence of RT of RNA preparations used; ACT, amplification product from
an RT-PCR assay targeting host -actin mRNA. Input was normalized to
the host -actin mRNA. Sizes of the amplification products are given
in the legend to Fig. 1.
|
|
 |
DISCUSSION |
Active ocular or urogenital infection with C. trachomatis represents a clinically significant event. However, it
is now clear that long-term, persistent infection with this organism
often engenders severe and difficult-to-treat sequelae. Similarly, the pneumonia resulting from respiratory infection by C. pneumoniae can be significant, but increasing evidence supports
both the existence and the clinical importance of chronic infection
with this organism. Evidence also argues that this latter state may be
of the most import in terms of overall human health. A good deal of
information is currently available concerning biochemical and molecular
genetic characteristics of persistent C. trachomatis. For
example, morphologic and microbiologic studies indicate that during
persistence, cells of this organism are characterized by a reduced
capacity for the enlarged and aberrantly shaped RB to undergo cell
division but that these abnormal intracellular organisms continue to
replicate their genomes (2). Failure to undergo cell
division has been noted for IFN-
-mediated induction of persistence in C. pneumoniae (22), and data in the present
report provide an explanation for that lack of cytokinesis. Results of
RT-PCR analyses, targeting C. pneumoniae genes whose
products are required for chromosomal DNA replication and partition,
indicate that those genes are expressed during IFN-
-induced
persistent infection. In contrast, genes required for bacterial cell
division either are not expressed or are expressed only at an extremely
low level during persistence, thus essentially eliminating
cytokinesis during this growth state. The functional result of
expression of DNA replication and segregation genes by the
bacterium should be accumulation of chlamydial chromosome; the results
presented here confirm that C. pneumoniae DNA does indeed
accumulate during cytokine-induced persistence, although the level of
accumulation is low.
We did not attempt to quantitate relative transcript levels for the
C. pneumoniae genes assayed in either untreated or
IFN-
-treated infected HEp-2 cells. Nonetheless, it is unlikely that
the ftsK and ftsW mRNAs were missed in the
analysis of the high-dose-cytokine-treated samples. Control studies not
shown here indicated that the relative sensitivities of the RT-PCR
assay systems employed are approximately equivalent, and each of the
assays routinely identifies the targeted transcripts from 10 to 30 bacterial cells. In the untreated infected cells, amplified products
from the dnaA, mutS, minD,
polA, ftsK, and ftsW cDNA were
demonstrable even after the first round of the nested PCR. In the
low-dose-rIFN-
-treated cells, products from the replication-related
genes were easily identifiable after the two amplification rounds, as
they were in cDNA from the high-dose-cytokine-treated cells. No
products for the two cytokinesis-related genes could be identified even
after the second, nested amplification in cells treated with 0.50 ng of
cytokine per ml, although the nonnested assays for primary transcripts
from the rRNA operons gave clear products from the same RNA-cDNA
preparations. The important point is that we could identify no products
derived from either of the cytokinesis-related mRNAs in the
high-dose-rIFN-
-treated infected HEp-2 cells, indicating that
expression of the two cell division-related genes is severely
attenuated, even if it is not completely abolished, during
cytokine-induced persistent C. pneumoniae infection.
This study provides important new information regarding gene regulation
patterns intrinsic to intracellular chlamydial growth, during both
active and persistent infection. Clearly, differential gene expression
does occur in these two states, almost certainly as a result of
modulation of the host cell environment. One mechanism by which
chlamydiae might sense host environmental changes is through a
two-component signaling system, as has been described for a variety of
other bacterial pathogens (13). For example, a histidine
kinase (designated Cpn 0584; http://www.stdgen.lanl.gov) has been
identified in the C. pneumoniae genome, and this enzyme shows possible two-component regulatory activity. Importantly, a recent
study has shown that C. trachomatis exhibits differential, developmentally regulated expression of its three sigma factors, and it
has been postulated that this pattern of expression reflects a more
global pattern of chlamydial gene expression (25).
Congruent information is not yet available for transcription of
C. pneumoniae sigma factor genes, but experiments are now
under way to meet this need. The present study necessarily required
selecting genes to study their transcriptional activity under various
growth conditions. More complete analysis of C. pneumoniae
and host cell transcription patterns will require microarray analyses.
These studies are also in progress.
 |
ACKNOWLEDGMENTS |
This work was supported by NIH grants AR-42541 and AI-44055
(A.P.H.) and AI 19782 and AI 42790 (G.I.B.).
G.I.B. and A.P.H. contributed equally to this work.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medical Microbiology and Immunology, University of Wisconsin School of Medicine, 436 Service Memorial Institute, 1300 University Ave., Madison, WI 53706. Phone: (608) 263-2494. Fax: (608) 265-0683. E-mail:
gibyrne{at}facstaff.wisc.edu.
Editor:
J. T. Barbieri
 |
REFERENCES |
| 1.
|
Beatty, W. L.,
R. P. Morrison, and G. I. Byrne.
1994.
Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis.
Microbiol. Rev.
58:686-699[Abstract/Free Full Text].
|
| 2.
|
Beatty, W. L.,
R. P. Morrison, and G. I. Byrne.
1995.
Reactivation of persistent Chlamydia trachomatis infection in cell culture.
Infect. Immun.
63:199-205[Abstract].
|
| 3.
|
Blythe, M. J.,
B. P. Katz,
B. E. Batteiger,
J. A. Ganser, and R. B. Jones.
1992.
Recurrent genitourinary chlamydial infection in sexually active female adolescents.
J. Pediatr.
121:487-493[CrossRef][Medline].
|
| 4.
|
Bremer, H., and G. Churchwood.
1991.
Control of cyclic chromosome replication in Escherichia coli.
Microbiol. Rev.
55:459-475[Abstract/Free Full Text].
|
| 5.
|
Donachie, W. D.
1993.
The cell cycle of Escherichia coli.
Nucleic Acids Res.
18:6713-6721[Free Full Text].
|
| 6.
|
Gerard, H. C.,
J. A. Whittum-Hudson, and A. P. Hudson.
1997.
Genes required for assembly and function of the protein synthetic system in Chlamydia trachomatis are expressed early in elementary to reticulate body transformation.
Mol. Gen. Genet.
255:637-642[CrossRef][Medline].
|
| 7.
|
Gérard, H. C.,
H. R. Schumacher,
H. El-Gabalawy,
R. Goldback-Mansky, and A. P. Hudson.
2000.
Chlamydia pneumoniae infecting the human synovium are viable and metabolically active.
Microb. Pathog.
29:17-24[CrossRef][Medline].
|
| 8.
|
Grayston, J. T.
2000.
Background and current knowledge of Chlamydia pneumoniae and atherosclerosis.
J. Infect. Dis.
181:S402-S410.
|
| 9.
|
Hahn, D. L.,
R. W. Dodge, and R. Golubjatnikov.
1991.
Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult onset asthma.
JAMA
266:225-230[Abstract].
|
| 10.
|
Hammerschlag, M. R.,
K. Chirgwin,
P. M. Roblin,
M. Gelling,
W. Dumornay,
L. Mandel,
P. Smith, and J. Schachter.
1992.
Persistent infection with Chlamydia pneumoniae following acute respiratory illness.
Clin. Infect. Dis.
14:178-182[Medline].
|
| 11.
|
Harwood, J. (ed.).
1996.
Basic DNA and RNA protocols.
Humana Press, Totowa, N.J.
|
| 12.
|
Hiratsuka, M.,
Y. Agatsuma, and M. Mizugaki.
1999.
Rapid detection of CYP2C9*3 alleles by real time fluorescence PCR based on SYBR green.
Genet. Metab.
68:357-362.
|
| 13.
|
Hoch, J. A., and T. J. Silhavy (ed.).
1995.
Two-component signal transduction.
ASM Press, Washington, D.C.
|
| 14.
|
Inman, R. D.,
J. A. Whittum-Hudson,
H. R. Schumacher, and A. P. Hudson.
2000.
Chlamydia and associated arthritis.
Curr. Opin. Rheumatol.
12:254-262[CrossRef][Medline].
|
| 15.
|
Kalayoglu, M. V., and G. I. Byrne.
1998.
Induction of macrophage foam cell formation by Chlamydia pneumoniae.
J. Infect. Dis.
177:725-729[Medline].
|
| 16.
|
Kuo, C.-C.,
A. Shor,
L. A. Campbell,
H. Fukushi,
D. L. Patton, and J. T. Grayston.
1993.
Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries.
J. Infect. Dis.
167:841-849[Medline].
|
| 17.
|
Kutlin, A.,
P. M. Roblin, and M. R. Hammerschlag.
1999.
In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model.
Antimicrob. Agents Chemother.
43:2268-2272[Abstract/Free Full Text].
|
| 18.
|
Laitinen, K.,
A. L. Laurila,
M. Leinonen, and P. Saikku.
1996.
Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment.
Infect. Immun.
64:1488-1490[Abstract].
|
| 19.
|
Leitman, T.,
D. Brooks,
J. Moncada,
J. Schachter,
C. Dawson, and D. Dean.
1998.
Chronic follicular conjunctivitis associated with Chlamydia psittaci or Chlamydia pneumoniae.
Clin. Infect. Dis.
26:1335-1340[Medline].
|
| 20.
|
Malinverni, R.,
C.-C. Kuo,
L. A. Campbell, and J. T. Grayston.
1995.
Reactivation of Chlamydia pneumoniae lung infection in mice by cortisone.
J. Infect. Dis.
172:593-594[Medline].
|
| 21.
|
Mathews, S. A.,
K. M. Volp, and P. Timms.
1999.
Development of a quantitative gene expression assay for Chlamydia trachomatis identified temporal expression of sigma factors.
FEBS Lett.
458:354-358[CrossRef][Medline].
|
| 22.
|
Mehta, S. J.,
R. D. Miller,
J. A. Ramirez, and J. T. Summersgill.
1998.
Inhibition of Chlamydia pneumoniae replication in HEp-2 cells by interferon- : role of tryptophan catabolism.
J. Infect. Dis.
177:1326-1331[Medline].
|
| 23.
|
Saikku, P.,
M. Leinonen,
K. Mattila,
M. R. Ekman,
M. S. Nieminen,
P. H. Makela,
J. Huttunen, and V. Valtonen.
1988.
Serologic evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.
Lancet
ii:983-985.
|
| 24.
|
Stephens, R. S.
1994.
Molecular genetics of Chlamydia, p. 377-386.
In
W. R. Bowie, H. D. Caldwell, M. A. Chernesky, et al. (ed.), Chlamydial infections. Societa Editrice Esculapio, Bologna, Italy.
|
| 25.
|
Timms, P., and S. Mathews.
2000.
Gene regulation in Chlamydia.
Proc. Eur. Soc. Chlamydia Res.
4:13-16.
|
| 26.
|
Weinstock, H.,
D. Dean, and G. Bolan.
1994.
Chlamydia trachomatis infection.
Infect. Dis. Clin. N. Am.
8:797-819[Medline].
|
Infection and Immunity, September 2001, p. 5423-5429, Vol. 69, No. 9
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.9.5423-5429.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Murata, M., Azuma, Y., Miura, K., Rahman, Mohd. A., Matsutani, M., Aoyama, M., Suzuki, H., Sugi, K., Shirai, M.
(2007). Chlamydial SET domain protein functions as a histone methyltransferase. Microbiology
153: 585-592
[Abstract]
[Full Text]
-
Goellner, S., Schubert, E., Liebler-Tenorio, E., Hotzel, H., Saluz, H. P., Sachse, K.
(2006). Transcriptional Response Patterns of Chlamydophila psittaci in Different In Vitro Models of Persistent Infection.. Infect. Immun.
74: 4801-4808
[Abstract]
[Full Text]
-
Mukhopadhyay, S., Miller, R. D., Sullivan, E. D., Theodoropoulos, C., Mathews, S. A., Timms, P., Summersgill, J. T.
(2006). Protein Expression Profiles of Chlamydia pneumoniae in Models of Persistence versus Those of Heat Shock Stress Response. Infect. Immun.
74: 3853-3863
[Abstract]
[Full Text]
-
Ikejima, H., Friedman, H., Yamamoto, Y.
(2006). Chlamydia pneumoniae infection of microglial cells in vitro: a model of microbial infection for neurological disease.. J Med Microbiol
55: 947-952
[Abstract]
[Full Text]
-
Gerard, H C, Whittum-Hudson, J A, Schumacher, H R, Hudson, A P
(2006). Synovial Chlamydia trachomatis up regulates expression of a panel of genes similar to that transcribed by Mycobacterium tuberculosis during persistent infection. Ann Rheum Dis
65: 321-327
[Abstract]
[Full Text]
-
Rahman, Mohd. A., Azuma, Y., Fukunaga, H., Murakami, T., Sugi, K., Fukushi, H., Miura, K., Suzuki, H., Shirai, M.
(2005). Serotonin and melatonin, neurohormones for homeostasis, as novel inhibitors of infections by the intracellular parasite chlamydia. J Antimicrob Chemother
56: 861-868
[Abstract]
[Full Text]
-
Teig, N, Anders, A, Schmidt, C, Rieger, C, Gatermann, S
(2005). Chlamydophilapneumoniae and Mycoplasma pneumoniae in respiratory specimens of children with chronic lung diseases. Thorax
60: 962-966
[Abstract]
[Full Text]
-
Hermann, C., Gueinzius, K., Oehme, A., von Aulock, S., Straube, E., Hartung, T.
(2004). Comparison of Quantitative and Semiquantitative Enzyme-Linked Immunosorbent Assays for Immunoglobulin G against Chlamydophila pneumoniae to a Microimmunofluorescence Test for Use with Patients with Respiratory Tract Infections. J. Clin. Microbiol.
42: 2476-2479
[Abstract]
[Full Text]
-
Hogan, R. J., Mathews, S. A., Mukhopadhyay, S., Summersgill, J. T., Timms, P.
(2004). Chlamydial Persistence: beyond the Biphasic Paradigm. Infect. Immun.
72: 1843-1855
[Full Text]
-
Dechend, R., Gieffers, J., Dietz, R., Joerres, A., Rupp, J., Luft, F. C., Maass, M.
(2003). Hydroxymethylglutaryl Coenzyme A Reductase Inhibition Reduces Chlamydia pneumoniae-Induced Cell Interaction and Activation. Circulation
108: 261-265
[Abstract]
[Full Text]
-
Slepenkin, A., Motin, V., de la Maza, L. M., Peterson, E. M.
(2003). Temporal Expression of Type III Secretion Genes of Chlamydia pneumoniae. Infect. Immun.
71: 2555-2562
[Abstract]
[Full Text]
-
Erkens, J.A., Klungel, O.H., Herings, R.M.C., Stolk, R.P., Spoelstra, J.A., Grobbee, D.E., Leufkens, H.G.M.
(2002). Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients. Eur Heart J
23: 1575-1579
[Abstract]
[Full Text]
-
Molestina, R. E., Klein, J. B., Miller, R. D., Pierce, W. H., Ramirez, J. A., Summersgill, J. T.
(2002). Proteomic Analysis of Differentially Expressed Chlamydia pneumoniae Genes during Persistent Infection of HEp-2 Cells. Infect. Immun.
70: 2976-2981
[Abstract]
[Full Text]
-
Hermann, C., Graf, K., Groh, A., Straube, E., Hartung, T.
(2002). Comparison of Eleven Commercial Tests for Chlamydia pneumoniae-Specific Immunoglobulin G in Asymptomatic Healthy Individuals. J. Clin. Microbiol.
40: 1603-1609
[Abstract]
[Full Text]